RAMUCIRUMAB IN A COMBINATION WITH IRINOTECAN-BASED TWO-COMPONENT THERAPY REGIMEN AS THE SECOND LINE FOR THE TREATMENT OF DISSEMINATED GASTRIC CANCER. CASE REPORT
- Autores: Titova T.A1, Besova N.S1, Gorbunova V.A1, Fedenko A.A1, Malikhova O.A1
-
Afiliações:
- N.N. Blokhin National Medical Research Center of Oncology
- Edição: Nº 7 (2018)
- Páginas: 102-104
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295506
- ID: 295506
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Palavras-chave
Texto integral
Sobre autores
T. Titova
N.N. Blokhin National Medical Research Center of OncologyMoscow
N. Besova
N.N. Blokhin National Medical Research Center of Oncology
Email: besovans@mail.ru
PhD in Medical Sciences, Senior Researcher at the Department of Chemotherapy Moscow
V. Gorbunova
N.N. Blokhin National Medical Research Center of OncologyMoscow
A. Fedenko
N.N. Blokhin National Medical Research Center of OncologyMoscow
O. Malikhova
N.N. Blokhin National Medical Research Center of OncologyMoscow
Bibliografia
- https://www.cancer.org/cancer/stomach-cancer/ 4. detection-diagnosis-staging/survival-rates.html
- Wilson D., Hiller L., Geh J.I. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005;17:81-90.
- Fuchs C.S., Tomasek J., Yong C.J., Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31-39. PMID: 24094768. doi: 10.1016/S0140-6736(13) 61719-5].
- Wilke H., Muro K., Van Cutsem E., et al.; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a doubleblind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224-35. PMID: 25240821. doi: 10.1016/S1470-2045(14) 70420-6]
- Yang L., Jiang X., Yan H., et al. Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer. BMC Gastroenterol. 2018;18:43. PMID: 29609559. doi: 10.1186/s12876-018-0772-4.
- Tabernero J., Yoshino T., Cohn A.L., et al. RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499-508. PMID: 25877855. doi: 10.1016/S1470-2045(15)70127-0.
Arquivos suplementares
